Efficacy and safety of agomelatine oral administration (25 mg/day) in elderly patients suffering from major depressive disorder: an 6-week, randomised, double-blind, fixed-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 18 weeks.

Trial Profile

Efficacy and safety of agomelatine oral administration (25 mg/day) in elderly patients suffering from major depressive disorder: an 6-week, randomised, double-blind, fixed-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 18 weeks.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2017 Primary endpoint (The MADRS total score over 6 weeks) has been met.
    • 12 Apr 2017 New trial record
    • 05 Apr 2017 Results assessing safety and efficacy of Agomelatine using patient data from two phase III trials (ISRCTN57507360 and see CTP 283683), published in the International Clinical Psychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top